|
Segment Results Continued CHEMICALS Chemicals sales were .5 billion in 2004, compared with .4 billion in 2003 and .4 billion in 2002. Prices rose 22 percent versus 2003. Solvents and intermediates, chlorinated organics, vinyl chloride monomer ``VCM'' ; and EG all experienced higher prices in 2004. Volume was up 3 percent for 2004, with increases in chlorinated organics, caustic soda, VCM and EG despite a decline in volume related to the formation of MEGlobal, a new 50: joint venture with PIC, in the second quarter of 2004. Beginning on July 1, 2004, certain sales of EG were sourced through that joint venture. In 2003, prices increased 24 percent and volume grew 6 percent versus 2002. EG sales were up substantially from 2003 with prices increasing 31 percent and volume increasing 4 percent. Prices increased due to higher feedstock and energy costs and an improving supply demand balance. Volume increased as a result of increasing demand in the PET and polyester industries, which use EG as a raw material. While volume improved overall, it was significantly dampened by the formation of MEGlobal. VCM sales were up 40 percent due to a 33 percent increase in prices and a 7 percent increase in volume driven by strong industry demand for polyvinyl chloride ``PVC'' ; , which is the major end-use product for VCM. Caustic soda sales were up 5 percent versus 2003 due to a 9 percent increase in volume partially offset by a 4 percent decline in prices. Caustic soda prices hit bottom in the first half of 2004. Demand for caustic soda increased in the second half of 2004, improving industry supply demand balances and supporting significant price momentum in the latter part of 2004. Solvent and Intermediates sales were up 8 percent due to a 14 percent increase in price and a 6 percent decline in volume. The decline in volume was primarily due to the Company's exit of the ethanol business in the second quarter of 2004. EBIT was , 602 million in 2004 compared with 4 million in 2003 and a loss of million in 2002. EBIT in 2004 improved due to the combined impact of stronger volume, higher prices, higher operating rates and increased equity company earnings partially offset by rising feedstock and energy costs. Results for 2004 also included a gain of 9 million associated with the divestiture of assets in conjunction with the formation of MEGlobal in the second quarter of 2004 see Note C to the Consolidated Financial Statements ; . EBIT in 2003 increased from 2002 principally due to increased volume, higher prices and cost reductions partially offset by increased feedstock and energy costs. EBIT in 2002 was negatively impacted by costs related to the start-up of expanded VCM facilities in Freeport, Texas, and chlor-alkali facilities in Stade, Germany; and a million charge for the write-down of assets related to the shutdown of a chlor-alkali facility in Fort Saskatchewan, Alberta, Canada see Note F to the Consolidated Financial Statements.
Lation remains relatively high because of the length of time required to fully load patients with 1.7 to 2mg of Amiodarone. CLINICAL IMPLICATIONS: The attainment and maintenance of normal sinus rhythm postoperatively in open heart surgery patients with the perioperative use of Amiodarone has lead to 1 ; -Reduced resource utilization for the treatment of postoperative atrial fibrillation. 2 ; -Reduced length of stay . 3 ; Reduced risk of bleeding from anticoagulation. DISCLOSURE: Charles Oribabor, None. DOES ADJUNCTIVE TRANSMYOCARDIAL LASER REVASCULARIZATION TMR ; REDUCE POSTOPERATIVE ATRIAL FIBRILLATION IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING? Gary S. Allen MD * Osceola Regional Medical Center, Kissimmee, FL PURPOSE: Postoperative atrial fibrillation AF ; after coronary artery bypass grafting CABG ; may occur in as many as 30% of cases. Medical management of this problem is often ineffective. While the etiology for postoperative AF remains unclear, increased cardiac sympathetic nervous activity is a likely factor. Previous animal studies have shown that TMR with a Holmium: YAG laser can sympathectomize the regional myocardium. The purpose of this study is to examine the effect of TMR on the incidence of postoperative AF. METHODS: Fourteen U.S. centers participated in a nonrandomized study during the period from January 1, 2002 to March 31, 2005. Patients with diffuse multi small vessel coronary artery disease CAD ; who could not be completely revascularized by CABG alone compromise the study population. Patients were followed in-hospital and through 30 days. RESULTS: A total of 739 men 72% ; patients with a mean age of 64 11 years and a mean ejection fraction of 51% 10% underwent TMR. Among comorbidities hyperlipidemia: 83%; hypertenCABG sion: 78%; prior myocardial infarction: 36%; smoking: 59% ; , only diabetes 47% ; occurred more frequently compared to the Society of Thoracic Surgeons STS ; database for primary CABG p 0.05 ; . An on pump technique was used in 643 87% ; operations. Patients received an average of 3.0 1.1 bypass grafts and 22 9 TMR channels. At 30 days, all-cause mortality was 2.4%. The incidence of postoperative AF was 5.3%, and significantly lower p 0.001 ; than that reported for CABG alone in a multicenter 32% ; experience. CONCLUSION: Postoperative AF in the CABG patient increases CVA risk, length of stay and complicates patient management. While TMR has proven itself valuable in angina reduction for patients with diffuse CAD it's effect on postoperative AF has not been previously TMR demonstrated a described. Study patients undergoing CABG significantly lower incidence of postoperative AF compared to historical controls. This striking difference warrants further investigation. CLINICAL IMPLICATIONS: TMR with a Holmium: YAG laser may have a place in the prevention of AF in the post CABG patient. DISCLOSURE: Gary Allen, None. PREDICTORS OF POSTOPERATIVE PNEUMONIA FOLLOWING CARDIOPULMONARY BYPASS Rochelle M. Wynne RN * Mari Botti PhD Donald Esmore MBBS Deakin University, Melbourne, Australia PURPOSE: The purpose of this study was to determine which pre and or peri-operative factors predicted the development of pneumonia following surgery with cardiopulmonary bypass for coronary artery bypass grafting with or without valvular or other concomitant cardiothoracic surgery. METHODS: Data from July 1996 until December 2002 were retrieved from a single University affiliated, tertiary teaching hospital database. Pneumonia was diagnosed by one of the following: positive cultures of sputum, blood, pleural fluid, empyema fluid, transtracheal fluid or transthoracic fluid; consistent with clinical findings that included chest x-ray evidence of pulmonary infiltrate, elevated temperature, new productive cough or purulent sputum. Predictor selection was guided by previous studies examining pulmonary complications following cardiac surgery. The effect of 16 preoperative and 10 peri-operative variables on pneumonia was examined using direct entry multivariate logistic regression. RESULTS: Of 5364 cases, 342 6.4% ; patients were diagnosed with 12.6 years of age, with a pneumonia. Patients were on average 63.5 body mass index of 26.9 4.5 kg m2 and 27.8% n 1491 ; of the sample were female. Significant predictors of pneumonia from the preoperative context were gender OR 1.3, 95%CI: 1.014-1.653, p .05 ; , New York Heart Association Class III OR 0.753, 95%CI: 0.572-0.992, p .05 ; and emergency surgical status OR 0.645, 95%CI: 0.432-0.962, p .05 ; . From the peri-operative context perfusion time greater than 120 minutes OR 0.606, 95%CI: 0.473-0.777, p .001 ; , the need for mechanical support OR 0.380, 95%CI: 0.268-0.539, p .001 ; , peri-operative myocardial infarction OR 0.302, 95%CI: 0.110-0.831, p .05 ; and peri-operative stroke OR 0.281, 95%CI: 0.171-0.461, p .001 ; predicted postoperative pneumonia. While this model correctly classified 93.6% of cases it only explained 4.9% R2 ; of the variation in pneumonia outcome. CONCLUSION: Pre and peri-operative factors make a minimal contribution to predicting the risk of postoperative pneumonia in cardiac surgical candidates. CLINICAL IMPLICATIONS: Patient and process factors from the postoperative context require exploration and inclusion in multivariate models in order to develop reliable risk prediction strategies for pneumonia. DISCLOSURE: Rochelle Wynne, None.
Vancomycin peak levels when to check
TABLE 1 Patient Variables Baseline Period Number of Patients Age years ; Weight Kg ; Body Surface Area m2 ; Diabetes % ; Hypertension % ; Cardiac Surgery % ; CABG No. of Vessels Valve s ; Thoracic Aneurysms Lung Surgery % ; Hospital Days Before Surgery Antibiotic Prophylaxis % ; Cefazolin CeftazidimeVancomycin Other Vancomycin Cross Clamp time min ; Bypass Time min.
Departments of Medical Sciences Endocrine Oncology H.O., K.O., B.S., B.E. ; , Radiology A.S. ; , Nuclear Medicine U.G. ; , and Surgery C.J. ; and Uppsala University PET Center IMANET A.S., B.L., M.B. ; , Uppsala University Hospital, S-751 85 Uppsala, Sweden.
This work was supported in part by the university of sydney cancer research fund.
FINANCIAL AND RESOURCE IMPACT OF NITRIC OXIDE WEANING GUIDELINES Brian K. Walsh, BS, RRT-NPS, RPFT; Sara Nugent, RRT-NPS University of Virginia Health System, Charlottesville, Virginia. Background: The charge for the daily administration of Inhaled Nitric Oxide INO ; was set by INO Therapeutics at 5.00 per hour in January 2002 with a 96 hour cap of , 000. This high cost of administration has forced clinicians to evaluate their use of INO and strive to discontinue its use as soon as clinically possible. On May 15, 2002 we implemented the use of a Nitric Oxide Weaning Guideline to standardize our practice. Methods: In the ten months prior to the implementation of the INO Weaning Guideline, INO was administered to 36 patients Group A ; . In the 10 months following the implementation of the INO Weaning Guideline, INO was administered to 24 patients Group B ; . The date, time of initiation, and discontinuation of INO were recorded at the time of service by the Respiratory Therapist caring for the patients. The hourly charge for INO services was reported by the Pharmacy. Results and vaniqa.
Carmy Export offers a high standard product backed with over 30 years of experience and passion for agriculture. Carmy export is well known for it's specialization in conventional and organic sweet potatoes and for it's constant developing of additional strains including organic varieties. Our growing areas are located in the South and in the Center of Israel, where we benefit from an optimal climate. The cultivators are supervised by professional teams and meet Eurepgap and Nature's Choice standards. The main export variety we grow is the Georgia Jet which is known for its attractive red skin, deliciously moist and rustorange flesh packed with vitamin A. Our sweet potatoes are offered in different sizes: Baby, S, M, L1, L2, EL, and G. The packaging ranges are 6 kg and 15 kg cartons and are available in different sizes and styles according to customer's preferences. Carmy Export is committed to maintain the promise of its company name, so our customers consistently benefit from the highest growing standards, quality and service. Seasonal Calendar for Sweet Potatoes.
What is redman syndrome vancomycin
Summary: Objective: The participant will describe the treatment of coagulase-negative staphylococcal CoNS ; bacteremia with daptomycin. Background: Daptomycin was recently approved for the treatment of methicillin-susceptible and -resistant Staphylococcus aureus bloodstream infections. There are limited outcomes data for bacteremia due to other pathogens such as coagulase-negative staphylococci CoNS ; . Methods: The Cubicin Outcomes Registry & Experience collected data on daptomycin treatment in 2005. Surgical interventions were not collected. Clinically evaluable patients with blood cultures positive for CoNS were included. Clinical success cure + improvement ; and failure were determined at the end of therapy using standard definitions. Results: Seventy patients were identified; 51% were males and 33% were 66 years of age. Common comorbidities included hypertension 39% ; , cancer 37% ; and diabetes 20% ; . Fifty-two 74% ; patients were in an institutional setting 2 days before daptomycin therapy was initiated, 15 21% ; received daptomycin in an ICU and 11 16% ; were on dialysis. Fifty-seven 81% ; patients received prior antibiotic therapy, most commonly with vancomycin 54%; of which 39% clinically failed ; . Forty-three 61% ; patients had infections related to intravascular catheters or intravascular intracardiac foreign devices. The median daptomycin dose was 5.5 mg kg range 0.01 to 8 mg kg ; . 48% of patients received a dose of 6 mg kg and 34% received 4 mg kg; 1 patient received 0.01 mg kg daptomycin via antibiotic lock. The median duration of daptomycin therapy was 11 days 1-370 days ; . Clinical success was achieved in 97%. Nine 13% ; patients had an adverse event reported; adverse events were assessed as possibly related to daptomycin in five cases; one of these events was characterized as serious. Conclusions: Daptomycin appeared to provide effective and well-tolerated therapy for the treatment of CoNS bacteremia. Daptomycin is frequently given in doses lower than that labeled for use in bacteremia 6 mg kg ; , indicating additional educational efforts are needed. Further studies are needed to confirm these findings. References: 1. Fowler VG Jr., Boucher H, Corey G, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006; 355: 653-665. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of Grampositive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006; 26: 347-352 and velcade.
Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390-8. Becker K, Friedrich AW, Lubritz G, Weilert M, Peters G, Von Eiff C. Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J Clin Microbiol 2003; 41: 1434-9. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32. Sakoulas G, Moellering RC, Jr., Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006; 42 Suppl 1: S40-50. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93. Caiazza NC, O'Toole GA. Alpha-toxin is required for biofilm formation by Staphylococcus aureus. J Bacteriol 2003; 185: 3214-7. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis 2002; 2: 677-85. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230-7. Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin Infect Dis 2006; 42: 224-33. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-64. Schentag JJ, Klugman K.P., Yu V.L., et al. Streptococcus pneumoniae bacteremias: pharmacodynamic correlations with outcome and macrolide resistance: a controlled study in press ; . Int J Antimicrob Agents 2007. Greenberg D DR, Klugman K, Madhi SA, Feldman C, Roberts S, Morris A, Chedid MBF, Chiou CC, Yu VL. Streptococcus pneumoniae serotypes causing meningitis in children and adults. 14th Intersci Conf Antimicrob Ag Chemother. Washington, DC., 2004. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38: 994-1000. Fenton C, Keating GM, Curran MP. Daptomycin. Drugs 2004; 64: 445-55; discussion 457-8. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005; 55: 2838. Schriever CA, Fernandez C, Rodvold KA, Danziger LH. Daptomycin: a novel cyclic lipopeptide antimicrobial. J Health Syst Pharm 2005; 62: 1145-58. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138: 135-42. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36: 159-68.
Vancomycin e test
Cal species of human origin by biochemical and physiological tests. Appl. Microbiol. 23: 1131-1139. 4. Fekety, F. R., and P. Weiss. 1967. Antibiotic synergism: enhanced susceptibility of enterococci to combinations of streptomycin and~penicillins or cephalosporins, p. 156-164. Antimicrob. Agents Chemother. 1966. 5. Friedberg, C. K., K. M. Rosen, and P. A. Bienstock. 1968. Vancomycin therapy for enterococcal and streptococcus viridans endocarditis. Arch. Int. Med. 122: 134-140. 6. Jawetz, E., and M. Sonne. 1966. Penicillin-streptomycin in treatment of endocarditis. N. Engl. J. Med. 274: 710-715. 7. Lee, C. C., E. B. Hert, and R. C. Anderson. 1970. Pharmacological and toxological studies on cephalothin. Clin. Med. 70: 1123-1138. 8. Mandell, G. L., D. Kaye, M. E. Levison, and E. W. Hook. 1970. Pnterococcal endocarditis. Arch. Iht. Med. 125: 258-264. 9. Medrek, T. F., and E. M. Barnes. 1962. The physiological and serological properties of Streptococcus bovis and related organisms isdlated froth cattle and sheep. J. Appl. Bacteriol. 25: 169-179. 10. Mildvan, D., S. Z. Hirschman, B. R. Meyers, and G. T. Keusch. 1972. Extracellular cephalosporinases produces by gram-negative bacilli. Can. J. Microbiol. 18: 1039-1043. 11. Miles, A. A., and S. S. Misra. 1938. The estimation of the bactericidal powor of the blood. J. Hyg. 38: 732-749. 12. Moellering, R. C., Jr., C. Wennerstern, T. Medrek, and A. N. Weinberg. 1971. Prevalence of high-level resistance to aminoglycosides in clinical isolates of enterococci, p. 335-340. Antimicrob. Agents Chemother. 1970. 13. Moellering, R. C., Jr., C. Wennersten, atid A. N. Weinberg. 1971. Studies on antibiotic synergism against enterococci. I. Blacteriologic studies, J. Lab. Clin. Med and ventavis.
Recently when the 2000-pound gorilla, namely Medicare, got into the game. On February 1, 2005, Mark McClellan, MD, an economist internist and the Director of the Center for Medicare and Medicaid Services CMS ; , announced that ten physician groups would be enrolled in a pay-for-performance trial, dubbed the Medicare Physician Group Practice Demonstration.2 These practices included the Geisinger Health System in Pennsylvania, DartmouthHitchcock in New Hampshire, Deaconess Billings in Montana, Forsyth in Winston-Salem, the University of Michigan Faculty Group Practice, and others. Unlike the Premier experiment, which involved only technical or hospital fees, this new venture would put physician revenue at risk. Each group will have a different area of concentration. For instance, Geisinger will emphasize the use of its electronic medical record to improve access to health care information among Medicare beneficiaries in rural Pennsylvania. Other participants will optimize treatment of patients with diabetes, congestive heart failure, hypertension and COPD utilizing means such as home care, preventive health, and disease management programs. Other programs have arisen that share a similar philosophy. In California, the Integrated Healthcare Association, formed in 1994 by six health plans encompassing over seven million members, is unique in its incorporation of patient satisfaction into the bonus formula for its pay-for-performance initiative. In 2004, more than million was distributed on the basis of clinical quality 50% ; , patient satisfaction 40% ; and computer investments 10% ; . Kaiser Permanente initially played an advisory role only, because the medical group incentive payments did not fit with its integrated health plan-medical group structure. However, the two California Permanente Medical Groups began reporting data on clinical and satisfaction measures to the IHA initiative in 2005 and 2006. ; Hospital Compare, a cooperative effort of CMS, the Department of Health and Human Services, and the Hospital Quality Alliance, was introduced in April 2005 to provide the.
Vancomycin prescribing information
Figure 7. Histological differences in the embryogenic cultures grown in the presence or the absence of Ca2 in MS3. A, Longitudinal section of torpedo-stage embryo grown under optimal differentiation conditions showing distinct radical and plumular ends and vascular procambial strands. B, Section of an enlarged clump from cultures grown under Ca2 -chelated conditions showing compactly arranged cells but no trace of vascular development. Scale bar 150 m and vesicare.
1. CODE REQUIREMENTS When gas piping runs are located below grade in contact with earth or other material that could corrode the piping, codes require that the gas piping shall be protected against corrosion. When piping is installed underground beneath buildings, codes require that the piping shall be encased in a conduit sealed inside of the building and vented above grade to the outside. The conduit shall be designed to withstand the superimposed loads. NO FITTINGS OR COUPLINGS ARE PERMITTED BENEATH BUILDINGS. 2. REGIONAL MODEL CODES TracPipe PS patented ; and PS-II patent-pending ; installations conform to the underground fuel gas installation requirements of: The National Fuel Gas Code NFPA 54 The International Fuel Gas Code The Uniform Plumbing Code 2003 UPC.
Fingers or toes to cover and protect extremities during cold or hot therapy. Sold in pairs and vfend.
Vancomycin no prescription
Canker sore alcohol, reflux gas, malignancy fever, internal medicine match statistics and aerosol halo. Epidermal growth factor mw, pollen count ny, aortic valve replacement complications and glioma cure or mosaic dallas apartments.
Mrsa vancomycin allergic
Vzncomycin, vancomyxin, gancomycin, vancomycni, vancimycin, vancmycin, vanfomycin, vancokycin, vabcomycin, vancomyckn, vanconycin, vancomycim, vacnomycin, vqncomycin, vancomyicn, vanc0mycin, vncomycin, vancomtcin, vwncomycin, vancomyycin.
Vancomycin pharmacokinetics calculator
Vancomycin peak levels when to check, what is redman syndrome vancomycin, vancomycin e test, vancomycin prescribing information and vancomycin no prescription. Mrsa vancomycin allergic, vancomycin pharmacokinetics calculator, vancomycin liquid dosing and vancomycin in pregnancy or iv vancomycin package insert.
|
